Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults and helps improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers HbA1c and fasting plasma glucose as monotherapy. - Combination therapy with metformin: provides additional glycaemic reduction when metformin alone is insufficient. - Adjunct to diet and exercise: supports lifestyle measures to achieve target blood glucose levels.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient and usually mild. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

Linagliptin should be prescribed after evaluating patient‑specific factors and monitoring for adverse events. - Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: monitor liver enzymes during treatment. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Elderly patients: start at recommended dose and observe for tolerance. - Pregnancy and lactation: avoid unless benefits clearly outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several concomitant medicines, requiring clinical awareness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure and risk of adverse effects. - Rifampin (CYP3A4 inducer): may reduce linagliptin efficacy. - Insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose control; monitor blood glucose. - ACE inhibitors: observe blood pressure and renal function. - Warfarin: check INR regularly as glycaemic changes can influence anticoagulation.